Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab

Journal of Clinical Oncology

Volumn 33, Issue 18, 2015, Pages 2013-2020

  McDermott, David F ^a   Choueiri, Toni K ^b   Puzanov, Igor ^c   Hodi, Stephen ^c   Drake, Charles G ^d   Brahmer, Julie R ^d   Hammers, Hans J ^d   Topalian, Suzanne L ^d   Pardoll, Drew M ^d   Sznol, Mario ^e   Powderly, John D ^f   Smith, David C ^g   Carvajal, Richard D ^h   Wigginton, Jon M ⁱ   Kollia, Georgia D ⁱ   Gupta, Ashok ⁱ   McDonald, Dan ⁱ   Sankar, Vindira ⁱ   Sosman, Jeffrey A ^j   Atkins, Michael B ^k  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Carolina BioOncology Institute   (United States)

^g UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j VANDERBILT INGRAM CANCER CENTER   (United States)

^k GEORGETOWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; INSTITUTIONAL REVIEW; KIDNEY CARCINOMA; KINETICS; MALE; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; OUTPATIENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; IMMUNOLOGY; KIDNEY NEOPLASMS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATIENT SAFETY; PROGRAMMED CELL DEATH 1 RECEPTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929361060     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.1041     Document Type: Article

References (38)

1. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
2. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370:210-2111, 2007
3. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
4. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007
5. McDermott DF, Regan MM, Clark JI, et al: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133-141, 2005
6. Keir ME, Butte MJ, Freeman GJ, et al: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704, 2008
7. Thompson RH, Gillett MD, Cheville JC, et al: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 101:17174-17179, 2004
8. Keir ME, Freeman GJ, Sharpe AH: PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol 179:50-5070, 2007
9. Taube JM, Anders RA, Young GD, et al: Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra37, 2012
10. Dong H, Strome SE, Salomao DR, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8:793-780, 2002
11. Blank C, Kuball J, Voelkl S, et al: Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119:317-327, 2006
12. Ahmadzadeh M, Johnson LA, Heemskerk B, et al: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-1544, 2009
13. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
14. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:244-245, 2012
15. Cho DC, Sosman JA, Sznol M, et al: Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31:285s, 2013 (suppl 15s; abstr 4505)
16. McDermott DF, Drake CD, Sznol M, et al: Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC). J Clin Oncol 30:278s, 2012 (suppl; abstr 4505)
17. Nurieva RI, Liu X, Dong C: Molecular mechanisms of T-cell tolerance. Immunol Rev 241:133-144, 2011
18. Hamanishi J, Mandai M, Iwasaki M, et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 104:3360-3365, 2007
19. Wang C, Thudium KB, Han M, et al: In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2:846-856, 2014
20. Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175, 2010
21. Wolchok JD, Hoos A, O'Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
22. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (version 3.0). http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
24. Clopper C, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413, 1934
25. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
26. Drake CG, McDermott DF, Sznol M, et al: Survival, safety and response duration results of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase 1 trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. J Clin Oncol 31:287s, 2013 (suppl 15s; abstr 4514)
27. Topalian SL, Sznol M, Brahmer JR, et al: Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. J Clin Oncol 31:173s, 2013 (suppl 15s; abstr 3002)
28. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
29. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
30. Motzer RJ, Escudier B, Oudard S, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116:4256-4426, 2010
31. Hutson T, Escudier B, Esteban E, et al: Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: Results from the INTORSECT trial. Ann Oncol 23, 2012 (suppl 9; abstr LBA22)
32. Motzer RJ, Escudier B, Tomczak P, et al: Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14:552-562, 2013
33. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-1030, 2014
34. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
35. Callahan MK HC, Curran MA, Hollman T, et al: Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. J Clin Oncol 31:173s, 2013 (suppl 15s; abstr 3003)
36. Grosso J HC, Inzunza D, Cardona DM, et al: Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 31:177s, 2013 (suppl 15s; abstr 3016)
37. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
38. Atkins MB, Bukowski RM, Escudier BJ, et al: Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference. Cancer 115:2247-2251, 2009 (suppl)